TY - JOUR
T1 - The case for an HIV cure and how to get there
AU - Sunnylands 2019 Working Group
AU - Dybul, Mark
AU - Attoye, Timothy
AU - Baptiste, Solange
AU - Cherutich, Peter
AU - Dabis, François
AU - Deeks, Steven G.
AU - Dieffenbach, Carl
AU - Doehle, Brian
AU - Goodenow, Maureen M.
AU - Jiang, Adam
AU - Kemps, Dominic
AU - Lewin, Sharon R.
AU - Lumpkin, Murray M.
AU - Mathae, Lauren
AU - McCune, Joseph M.
AU - Ndung'u, Thumbi
AU - Nsubuga, Moses
AU - Peay, Holly L.
AU - Pottage, John
AU - Warren, Mitchell
AU - Sikazwe, Izukanji
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/1
Y1 - 2021/1
N2 - In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
AB - In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
UR - https://www.scopus.com/pages/publications/85097897876
U2 - 10.1016/S2352-3018(20)30232-0
DO - 10.1016/S2352-3018(20)30232-0
M3 - Review article
C2 - 33271124
AN - SCOPUS:85097897876
SN - 2352-3018
VL - 8
SP - e51-e58
JO - The Lancet HIV
JF - The Lancet HIV
IS - 1
ER -